United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 15

Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 15 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderCumberland Pharmaceuticals · 46

Strongest available pathCumberland Pharmaceuticals · +149.6%

Widest latest marginTheravance Biopharma · 98.5%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1CPIX · Nasdaq

Cumberland Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2007Nashville, Tennessee$100.2M market cap

View full Companies Radar profile

46Cautious

Snapshot price$6.69as of page date

Monthly-close return+149.6%five-year window

FY2025 revenue$0.04BCUMBERLAND PHARMACEUTICALS INC

Net margin-6.4%FY2025

Prism attention12.3%share across these five

Filing track recordRevenue, USD billions

+27.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 6.2%

52-week position65% through range

$1.85$9.28

News mentions904

Community mentions0partial coverage

U.S.-scope patents260

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal68/100
Management stability90/100
Market position30/100
Capital-event signal15/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 1 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2PULM · Nasdaq

Pulmatrix

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2003Lexington, Massachusetts$5.4M market cap

View full Companies Radar profile

46Cautious

Snapshot price$1.47as of page date

Monthly-close return-90.8%five-year window

FY2025 revenue$0.01BPulmatrix, Inc.

Net margin-66.1%FY2025

Prism attention7.9%share across these five

Filing track recordRevenue, USD billions

+51.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 10.9%

52-week position7% through range

$1.16$5.50

News mentions577

Community mentions13partial coverage

U.S.-scope patents262

Prism InsightsWhat sits behind the readiness signal
Observed risk 10/100higher means more observed risk

Earnings signal57/100
Management stability90/100
Market position14/100
Capital-event signal75/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 1 asset-acquisition events and 7 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 4 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3PBYI · Nasdaq

Puma Biotechnology

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Los Angeles, California$470.3M market cap

View full Companies Radar profile

46Cautious

Snapshot price$9.11as of page date

Monthly-close return+30.0%five-year window

FY2025 revenue$0.23BPUMA BIOTECHNOLOGY, INC.

Net margin13.6%FY2025

P/E snapshot17.9xone ratio, not a verdict

Prism attention13.1%share across these five

Filing track recordRevenue, USD billions

-9.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -2.5%

52-week position92% through range

$4.30$9.51

News mentions964

Community mentions11partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal53/100
Management stability90/100
Market position3/100
Capital-event signal59/100
Innovation pulse12/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4TBPH · Nasdaq

Theravance Biopharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2001Francisco$884.7M market cap

View full Companies Radar profile

46Cautious

Snapshot price$17.04as of page date

Monthly-close return+130.3%five-year window

FY2025 revenue$0.11BTheravance Biopharma, Inc.

Net margin98.5%FY2025

P/E snapshot16.4xone ratio, not a verdict

Prism attention15.6%share across these five

Filing track recordRevenue, USD billions

+94.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 18.1%

52-week position50% through range

$13.08$21.03

News mentions1.1K

Community mentions0partial coverage

U.S.-scope patents1598

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal69/100
Management stability90/100
Market position8/100
Capital-event signal34/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 7 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5ELAN · NYSE

Elanco

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1954INDIANAPOLIS$11.95B market cap

View full Companies Radar profile

45Cautious

Snapshot price$23.92as of page date

Monthly-close return-25.0%five-year window

FY2025 revenue$4.71BElanco Animal Health Inc

Net margin-4.9%FY2025

P/E snapshot18.7xone ratio, not a verdict

Prism attention51.1%share across these five

Filing track recordRevenue, USD billions

-1.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -0.3%

52-week position63% through range

$17.11$27.98

News mentions3.8K

Community mentions85partial coverage

U.S.-scope patents813

Prism InsightsWhat sits behind the readiness signal
Observed risk 8/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position28/100
Capital-event signal69/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 23 M&A involvements, 18 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 2 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Cumberland Pharmaceuticals

+149.6%

Theravance Biopharma

+130.3%

Puma Biotechnology

+30.0%

Elanco

-25.0%

Pulmatrix

-90.8%

Latest revenue

USD billions, official filing scope shown on each company card.

Elanco

$4.71B

Puma Biotechnology

$0.23B

Theravance Biopharma

$0.11B

Cumberland Pharmaceuticals

$0.04B

Pulmatrix

$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Theravance Biopharma

98.5%

Puma Biotechnology

13.6%

Elanco

-4.9%

Cumberland Pharmaceuticals

-6.4%

Pulmatrix

-66.1%

Prism news attention

Normalized share across these five names; attention is not quality.

Elanco

51.1%

Theravance Biopharma

15.6%

Puma Biotechnology

13.1%

Cumberland Pharmaceuticals

12.3%

Pulmatrix

7.9%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Elanco leads the conversation

It holds 51.1% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $4.71B.

Price path

Cumberland Pharmaceuticals leads the available price paths

Its monthly-close return is +149.6% for the five-year window. At the other end, Pulmatrix is -90.8% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Theravance Biopharma has the widest latest margin

Its FY2025 net margin is 98.5%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Theravance Biopharma shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 16.4x while its five-year window price return is +130.3%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · CPIX

Cumberland Pharmaceuticals

904available Prism news records

Prism top themes

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+0.7%138 latest 12m vs 137 prior 12m

Machine-classified coverage tone

93.9% positive-1.6 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 11stock price 8investor conference 7share price 6rare disease clinical trials 6rare disease treatment 6company valuation 5generic drug approval 5

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-01 · trend and themes shown through 2026-06

Areas of research · PBYI

Puma Biotechnology

964available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Leadership & governance

Capital allocation & transactions

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-16.0%89 latest 12m vs 106 prior 12m

Machine-classified coverage tone

90.2% positive-3.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

business award 17industry award 17stock performance 13earnings report 12cancer biomarkers 12company valuation 11stock price 11neoadjuvant therapy breast cancer 10

Keyword tag occurrences in available Prism news records.

Coverage: 2011-05-24–2026-06-01 · trend and themes shown through 2026-06

Areas of research · TBPH

Theravance Biopharma

1,141available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+0.9%117 latest 12m vs 116 prior 12m

Machine-classified coverage tone

77.9% positive-13.7 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 22stock price 15share price 9stock surge 5earnings per share 5investment deal 4rare disease treatment 4gene therapy rare diseases 4

Keyword tag occurrences in available Prism news records.

Coverage: 2013-04-26–2026-07-16 · trend and themes shown through 2026-07

Areas of research · ELAN

Elanco

3,750available Prism news records

Prism top themes

Earnings & financial performance

113

Price action & investor response

Legal, arbitration & regulatory

Leadership & governance

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-23.3%532 latest 12m vs 694 prior 12m

Machine-classified coverage tone

83.9% positive+18.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

dairy cows 23vaccine formulation 23class action securities litigation 23quarterly results 22earnings report 20stock performance 19annual earnings 19milk production 18

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-01–2026-06-19 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

ELAN

Elanco

85 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 85 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

CPIX

Cumberland Pharmaceuticals

through 2026-04-24

Earnings releases 27Business contracts 3Asset acquisitions 1M&A 1Regulatory 1

2026-04-24
Asset acquisitions
Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canadian pharmaceutical company Apotex for $100m in cash.
2026-04-23
M&A
Under the terms of the agreement, Apotex will acquire Cumberland's line of branded pharmaceuticals for cash consideration of $100 million.
2026-03-03
Earnings releases
Net revenues for the full year 2025 were $44.5 million an 18% increase over the prior year period.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PULM

Pulmatrix

through 2026-04-18

Earnings releases 12M&A 5Business contracts 4Regulatory 4Leadership changes 1

2026-04-18
Earnings releases
Net Income Earnings Per Share Price/Earnings Ratio Pulmatrix $7.81 million 0.59 -$5.16 million ($1.41) -0.89
2026-03-26
M&A
Pulmatrix announced a definitive merger agreement with Eos SENOLYTIX, a biotechnology company focused on gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases.
2026-03-02
Regulatory
PUR3100, a Phase 2-ready asset, is an orally inhaled dihydroergotamine ("DHE") engineered with Pulmatrix's iSPERSE™ dry powder inhalation technology for the treatment of acute migraine has a Food and Drug Administration acceptance of an Investigational New Drug ("IND") application for PUR3100 and receipt of a "study may proceed" letter to proceed with a Phase 2 study.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PBYI

Puma Biotechnology

through 2026-02-04

Earnings releases 22Company announcements 4Listing / IPO 2Regulatory 1

2026-02-04
Company announcements
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 14,750 shares of Puma common stock to two new non-executive employees.
2025-11-06
Earnings releases
For the third quarter of 2025, total revenue was $54.5 million, of which $51.9 million was product revenue, net and $2.6 million was royalty revenue.
2025-02-14
Listing / IPO
Puma Biotechnology Inc. raised $138 million from a public offering of shares at $122.50 each.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TBPH

Theravance Biopharma

through 2026-04-13

Earnings releases 26Asset acquisitions 5Leadership changes 4Lawsuits 1

2026-04-13
Earnings releases
Analysts at Zacks Research issued their Q1 2028 earnings estimates for shares of Theravance Biopharma in a research note issued to investors on Thursday, April 9th. Zacks Research analyst Team forecasts that the biopharmaceutical company will earn $0.01 per share for the quarter.
2025-06-06
Lawsuits
On June 5, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Eugia Pharma to resolve ongoing patent litigation concerning the YUPELRI® inhalation solution.
2025-06-03
Asset acquisitions
Theravance Biopharma, Inc. (NASDAQ: TBPH) has reached a definitive agreement to sell its remaining royalty interest in Trelegy Ellipta to GSK plc (NYSE: GSK) for $225 million in cash.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ELAN

Elanco

through 2025-11-04

Earnings releases 10Lawsuits 2M&A 2Asset acquisitions 1Regulatory 1

2025-11-04
Earnings releases
Elanco beat analysts’ revenue expectations by 4.7% last quarter, reporting revenues of $1.24 billion, up 4.8% year on year.
2025-10-23
Lawsuits
Elanco 401k investors have sued the company.
2025-10-05
Regulatory
Based on supplemental scientific data, the FDA provided an update to Elanco’s Zenrelia label, removing the risk of fatal vaccine-induced disease from modified live virus vaccine from the labeling.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 71–78. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Cumberland Pharmaceuticals leads the readiness ranking

Its Prism readiness score is 46/100, the highest in this five-company comparison.

Open Cumberland Pharmaceuticals in Companies Radar

Scale and margin leadership sit with Elanco and Theravance Biopharma

Elanco has the largest displayed latest revenue at $4.71B; Theravance Biopharma has the widest displayed latest margin at 98.5%.

Open Elanco in Companies Radar Open Theravance Biopharma in Companies Radar

Comparisons

Strongest versus weakest available price path

Cumberland Pharmaceuticals is +149.6% for its five-year window; Pulmatrix is -90.8% for its five-year window.

Open Cumberland Pharmaceuticals in Companies Radar Open Pulmatrix in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $4.71B for Elanco to $0.01B for Pulmatrix. Entity and filing-period labels remain visible on the company cards.

Open Elanco in Companies Radar Open Pulmatrix in Companies Radar

Anomalies

Elanco has the widest attention-readiness rank gap

It ranks #1 by measured news attention (51.1%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Elanco in Companies Radar

Pulmatrix shows a price-operating divergence to inspect

Its displayed filing-revenue change is +51.0% while its available monthly-close return is -90.8%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Pulmatrix in Companies Radar

Explanations

Attention measures coverage volume, not quality

Elanco's 51.1% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Elanco in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Cumberland Pharmaceuticals's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 46/100 score.

Open Cumberland Pharmaceuticals in Companies Radar

Stress-test the largest divergence before forming a view

Compare Pulmatrix's profile with Cumberland Pharmaceuticals's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Pulmatrix in Companies Radar Open Cumberland Pharmaceuticals in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.